Adults with Von Hippel-Lindau disease to benefit from new treatment
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.
People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.
In December 2023, we published guidance on hybrid closed loop systems for type 1 diabetes. Ammaarah Ahmed reveals the positive impact this game-changing technology has made to her.
The Spanish Ministry of Health needs to ensure that digital health technologies adopted by the Spanish National Health Service are clinically safe, effective and offer value to the taxpayer. Find out how NICE International has helped them to do this.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.